sábado, 18 de febrero de 2012

Cascade Screening for Familial Hypercholesterolemia (FH) - a knol by Renée M. Ned

Cascade Screening for Familial Hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by abnormally high concentrations of low-density lipoprotein (LDL) cholesterol in the blood, which predisposes affected persons to premature coronary heart disease (CHD) and death. FH is one of the most common inherited disorders and the most common one known to cause premature CHD in people of European descent. The vast majority of people with FH have inherited a single mutation from one parent in either the LDL receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin/kexin type 9 (PCSK9) genes. Despite their greatly elevated risk of coronary heart disease, most individuals with FH remain undiagnosed, untreated, or inadequately treated.

Cascade screening is a mechanism for identifying people at risk for a genetic condition by a process of systematic family tracing. The National Institute for Health and Clinical Excellence in the United Kingdom recommends cascade screening of close biological relatives of people with a clinical diagnosis of FH in order to effectively identify additional FH patients. The ultimate goal of this testing is to reduce morbidity and mortality from heart disease in persons with FH through early diagnosis and effective disease management. The goal of this article is to outline the available evidence on the clinical validity and utility of cascade screening for FH, while emphasizing the availability, usefulness, and recommendation for including DNA testing (if the disease-causing mutation has been identified).

Clinical Scenario
A patient has been diagnosed with familial hypercholesterolemia (FH). Use cascade screening to identify biological relatives of the patient who are also affected with the disorder.  
Test Description
Identifying and contacting biological relatives of a person diagnosed with FH (the index case) and then systematically testing these relatives (first-, second-, third-, etc. degree) using a combination of serum LDL cholesterol concentration measurements and a variety of mutation detection or screening assays for mutations in the LDLR, APOB, or PCSK9 genes.
Public Health Importance
FH is one of the most common inherited disorders, with an estimated worldwide prevalence of 1 in 500 (0.2%), though the frequency is considerably higher in some populations because of a founder effect [1]. This estimate corresponds to approximately 13 million people worldwide and ~600,000 in the United States who have FH. The overwhelming majority of affected persons are heterozygotes (those who have inherited one disease-causing mutation). A smaller number of patients (~1 in 200,000) are compound heterozygotes (who have inherited one copy each of two different mutations), while persons with homozygous FH (who have inherited two identical disease-causing mutations) are extremely rare (~1 in 1 million).  
The elevated serum cholesterol levels associated with FH lead to a greatly elevated risk for coronary heart disease (CHD) and death [2]. In fact, for those with heterozygous FH, the cumulative risk for CHD is greater than 50% in men by the age of 50 and at least 30% in women by the age of 60 [3][4]. Persons with homozygous FH manifest an even more severe form of the disorder. There is variation in the onset and severity of atherosclerotic disease in persons with FH, since environmental, metabolic, and genetic factors influence the clinical phenotype [2][5][6].  
Overall, estimates are that fewer than 25% of persons with FH are diagnosed; and the majority remain untreated or improperly treated [7][8][9], though there are no recent estimates available for the United States [10]. (Persons may be treated for high cholesterol without knowledge that they have FH. False-negative diagnoses can result in inadequate treatment, while false-positive diagnoses may result in overtreatment.) 
Because of the high prevalence of FH among family members (50% of first-degree relatives of heterozygotes are affected), cascade screening has been shown to be a cost-effective method of identifying people with FH [3][11][12]. Early detection and treatment with statins have been shown to reduce morbidity and mortality among those with heterozygous FH [3][4][11]. 
Despite an international effort to improve the identification and management of patients with FH [7][9], few countries have established large-scale programs to systematically determine the FH status of relatives of these patients [13][14][15][16][17][18][19][20][21].  
 
Published Reviews, Recommendations and Guidelines 
 
Systematic evidence reviews
A systematic evidence review [3] was conducted during the formulation of guidelines from the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (see next subsection). 
Recommendations by independent group
The NICE guidelines on the identification and management of FH recommend cascade screening using a combination of genetic testing and LDL cholesterol concentration measurement "is recommended to identify affected relatives of those index individuals with a clinical diagnosis of FH. This should include at least the first- and second- and, when possible, third-degree biological relatives” [3][22].  
 
Guidelines by professional groups
Until recently, there were no formal clinical guidelines or recommendations in the United States regarding cascade screening for FH. However, in June 2011, the National Lipid Association issued guidelines strongly encouraging the use of cascade screening to identify persons with FH [23][24]. Also in June 2011, the European Society of Cardiology and the European Atherosclerosis Society jointly issued guidelines recommending family screening (and cascade screening, if resources are available) for the detection of FH [25]. In both of these guidelines, cascade screening does not necessarily incorporate genetic testing, though DNA analysis is noted as being useful in some cases [23][24] or is recommended whenever resources are available [25].
 
 
Evidence Overview 
Analytic Validity: Test accuracy and reliability in measuring the genomic markers of interest— mutations in the LDLR, APOB, or PCSK9 genes (analytic sensitivity and specificity). 
  • Mutations known to cause FH have been found in the LDL receptor (LDLR), apolipoprotein B (APOB), and proprotein convertase subtilisin/kexin type 9 (PCSK9) genes. Several methods are currently used to identify sequence changes in these genes [3][26][27]; and additional technologies are under development.
  • The analytic sensitivity and specificity of each DNA test for FH will depend on the particular mutations being assayed and on the population(s) tested. (Often, labs will initially test only for those mutations that are most prevalent in a particular population.)
  • Because of the number of common polymorphisms that exist and because some scanning methods are not very efficient in detecting large-scale genetic rearrangements, many diagnostic labs are switching to direct sequencing strategies to improve the sensitivity of their mutation detection efforts [26].

Clinical Validity: Test accuracy and reliability in identifying relatives of patients with FH (predictive value).
  • More than 1,000 mutations in the LDLR gene have been identified in patients with FH [27]; and DNA testing on this gene alone has been found to identify 70-80% of people with a definitive clinical diagnosis of FH and 20-30% of those whose diagnosis is less certain [3][27]. Researchers have estimated that mutations in the APOB and PCSK9 genes account for only about 5.5% and 1.5% of FH cases, respectively [27].
  • Current DNA testing for FH is not 100% sensitive because the disorder may be caused by a mutation that is not assessed. Therefore, not finding a mutation does not necessarily exclude a diagnosis of FH [3]. Research has shown that ~15% of people with FH do not have a mutation in their LDLR, APOB, or PCSK9 genes (though reliable estimates range from 12% to 48%) [27].
  • Conversely, though mutation screening for FH is highly specific, it may produce false positives because some sequence changes that are detected can be non-pathogenic [26][27][28]. However, a false positive mutation will likely become evident during cascade screening, since it should fail to consistently associate with the FH phenotype.
  • Since FH is a disease inherited in an autosomal dominant fashion, the identification of the true mutation responsible for the disease in a family allows for the definitive diagnosis of biological relatives who have the mutation [3] (i.e., 100% positive predictive value).
  • If a familial FH mutation is not identified or if genetic testing is not available, relatives of an FH patient can be diagnosed with the disorder on the basis of sex- and age-specific LDL cholesterol thresholds (as recommended by NICE) [3][22]. However, because of an overlap in LDL cholesterol levels between people with FH and those without, there is still diagnostic uncertainty in over 15% of individuals [3][29].  Relatives can also be diagnosed on the basis of specific clinical characteristics, such as the presence of xanthomas (though these are not present in all persons with FH).
  • Published studies on the clinical validity of diagnosing relatives using DNA-based criteria compared to clinical criteria have shown that a clinical diagnosis is less sensitive and leads to under-diagnosis [15][30][31][32], raising the possibility that relatives diagnosed by clinical criteria may, in fact, have another form of dyslipidemia (i.e., they may have been misdiagnosed).
 
Clinical Utility: Net benefit of cascade screening in improving health outcomes.
  • Data from the U.K. has shown that cascade screening reduces the average age at which FH patients are diagnosed [3].
  • Cascade screening has also resulted in increased percentages of people with FH on statins and has, subsequently, resulted in decreased lipid levels in these people [3][30][33].
  • Statin use has been shown to reduce both total cholesterol and LDL cholesterol in adults with FH; and early detection and treatment with statins have been shown to reduce morbidity and mortality among those with heterozygous FH [3][4][11]. In one of the few long-term cohort studies of FH patients, there was an ~80% reduction in the risk of first onset of CHD among those treated with statins compared to untreated patients [34]. This study mimicked a placebo-controlled primary prevention trial and is the highest quality evidence of the effect of statin treatment in FH patients. Results from another long-term prospective study examined mortality in heterozygous FH patients aged 20-79 years old and showed an overall 37% reduction in deaths from CHD since statins became widely available. (The reduction in coronary mortality was greater for primary CHD prevention than for secondary CHD prevention— 48% versus 25% reduction) [4]. Other researchers used the concept of population attributable fraction to estimate the proportion of the 5-year risk for CHD mortality that could potentially be prevented among first-degree relatives of FH patients by treating the hypercholesterolemia among the affected relatives. This proportion was 44% among male, and 57% among female, first-degree relatives aged 20-79 years [35]. Remarkably, this analysis estimated that 96-98% of the deaths due to CHD among those under the age of 40 could be prevented with cholesterol reduction [35].
  • Statin treatment has been shown to decrease total and LDL cholesterol concentrations in children with FH [3][36][37][38][39][40][41]. However, there is no evidence of the long-term health benefits of statin treatment in children with FH (such as delayed onset of, or reduced risk for, CHD), nor evidence of any benefits compared to the detection and treatment of the disorder in adulthood [38][42]. Nevertheless, there are studies that support cholesterol lowering in children based on surrogate markers of cardiovascular disease [such as carotid intima-media thickness (IMT)] [43][44][45][46], some of which note a significant deviation in carotid IMT from the age of 12 years in children with FH (compared to unaffected siblings) [45].  Increased carotid IMT is reversible by statins, though we lack information regarding when such changes become irreversible. 
  • Because cascade screening may identify fewer than 50% of people with FH (at least as estimated for the U.K. population) [3], research is needed to compare the utility of other strategies for identifying those with FH.
  • There are no published data on the clinical utility of cascade screening that includes DNA testing compared to cascade screening without genetic analysis. The National Lipid Association has identified several areas related to FH where further research is needed, including the cost-effectiveness of genetic screening [47].
  • Hard data are also lacking regarding whether FH identification by cascade screening (and subsequent treatment of FH patients) is more effective in improving health outcomes of these patients compared to other identification methods (e.g., general physician note searching, use of secondary care registries, or population screening).
  • The following issues may also affect the ability of cascade screening to reduce CHD and CHD-related deaths among relatives of FH patients:
    • The identification and diagnosis of index cases. It is unclear whether a screening program should be implemented to find FH index cases and, if so, what type of program would be best (e.g., population-based or opportunistic screening of adults; universal or targeted lipid screening of children) [11][12][38][48][49][50][51][52][53]. In addition, three groups have developed diagnostic criteria for FH. These criteria differ in their need for (and the sufficiency of) DNA testing and in their diagnostic effectiveness [1][3].
    • The possibility of variation in the severity of FH phenotypes according to the type of mutation (the genotype-phenotype relationship), particularly for LDLR. For example, LDL receptor-null mutations have been associated with higher blood LDL cholesterol levels compared with LDL receptor-defective mutations [2][46][54][55][56]. However, family-based and population-based studies have largely found that statin treatment efficacy or the risks of CHD or CHD-related mortality are not affected by LDLR mutation type [54][57][58]. Of note, the only subgroup analysis performed in a randomized, double-blinded trial showed that LDLR mutation type altered the LDL-lowering effect of the investigated statin, but this trend was not statistically significant [55].
    • Uncertainty surrounding when and how to pharmacologically treat lipid disorders in children. As noted previously, there is no evidence of the long-term health benefits or safety of statin treatment in children, as the longest follow-up period in studies was 2 years [36][37][39][40][41]. Therefore, even if a child with FH is identified through cascade screening, the issue of when to start drug therapy is not straightforward. The U.S. Preventive Services Task Force (USPSTF) has not issued specific recommendations for the treatment of children with FH, although it did note that statins are effective for reducing total and LDL cholesterol levels in these children [38][48]. The American Academy of Pediatrics recommends that in children and adolescents with heterozygous FH, initial intervention “is focused on changing the diet. However, if this approach does not lower LDL to an acceptable concentration, these children may be candidates for pharmacologic intervention” [50]. The American Heart Association is more aggressive, recommending the consideration of lipid-lowering therapy for children aged ≥10 years (and after the onset of menses for girls) whose LDL levels are “severely elevated” and that the age or LDL cutpoint at which such therapy is initiated may be even lower for children with additional cardiovascular risk factors [52][59].  The National Lipid Association says that consideration should be given to starting treatment in children with (heterozygous) FH at 8 years of age or older [53]. The recommendation from NICE is similar: “lipid-modifying drug therapy for a child or young person with (heterozygous) FH should usually be considered by the age of 10 years”, taking into account the presence of other cardiovascular risk factors and the family history of CHD [3][22].
      It is important to note, however, that lifestyle interventions are also an important component of the medical management of FH for both children and adults [22], since environmental and metabolic factors can influence the FH phenotype [5][6].  FH patients (including children) are encouraged to get adequate physical activity, eat a healthy diet, and to refrain from smoking.  Of note, however, a recent Cochrane review of randomized controlled trials found that currently available data are insufficient to reach any conclusions regarding the efficacy of different dietary interventions for FH patients, including a lack of data on the usefulness of dietary modification over and above lipid-lowering drug therapy [60].
    • The best means by which to contact relatives of an FH index case. This subject is currently under debate [61][62].
 
In summary, the clinical validity and utility of cascade screening for FH is dependent on a number of factors, including the criterion used to diagnose the disorder in the index case, the use of DNA testing in the index case and in relatives, and the nature of the benefit and possible harms of identifying and pharmacologically treating the disorder in childhood.  Nevertheless, cascade screening is a straightforward and highly effective way to identify persons who have FH.  
 
Links
 
Last updated: July 1, 2011  
Acknowledgments
We would like to thank Shelley Reyes, Nicole F. Dowling, and Cecelia Bellcross in the Office of Public Health Genomics (OPHG) at CDC for comments and guidance.  
Funding information
This work was supported by the Office of Public Health Genomics (OPHG), Office of Surveillance, Epidemiology, and Laboratory Services (OSELS), Centers for Disease Control and Prevention (CDC).  
  
Competing interests
The authors declare that no competing interests exist.  
 
 
Disclaimers
 
The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention (CDC). 
The CDC does not offer medical advice to individuals. If you have specific concerns about your health or genetic testing, we suggest that you discuss them with your health care provider. 

References

  1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004 Sep 1;160(5):407-20. Review. PubMed PMID: 15321837.
  2. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol. 2004 Sep 1;160(5):421-9. Review. PubMed PMID: 15321838.
  3. DeMott, K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M, Ritchie G, Nunes V, Davies D, Lee P, McDowell I, Neil A, Qureshi N, Rowlands P, Seed M, Stracey H, Thorogood M, Watson M. Clinical Guidelines and Evidence Review for Familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. 2008. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners.
  4. Neil A, Cooper J, Betteridge J, Capps N, McDowell I, Durrington P, Seed M, Humphries SE. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008 Nov;29(21):2625-33. Epub 2008 Oct 7. PubMed PMID: 18840879; PubMed Central PMCID: PMC2577142.
  5. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, van Lennep HW, Sijbrands EJ, Kastelein JJ. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004 Dec;256(6):482-90. PubMed PMID: 15554949.
  6. Jansen AC, van Wissen S, Defesche JC, Kastelein JJ. Phenotypic variability in familial hypercholesterolaemia: an update. Curr Opin Lipidol. 2002 Apr;13(2):165-71. Review. PubMed PMID: 11891419.
  7. World Health Organization (WHO). Familial Hypercholesterolaemia (FH): Report of a second WHO Consultation. 1999. Geneva.
  8. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ. 2000 Jul 15;321(7254):148. PubMed PMID: 10894692; PubMed Central PMCID: PMC27432.
  9. Williams RR, Hamilton-Craig I, Kostner G, Hegele RA, Hayden MR, et al. MEDPED: An Integrated Genetic Strategy for Preventing Early Deaths. Berg K, Boulyjenkov, V, Christen, Y (editors). Genetic Approaches to Noncommunicable Diseases. 1996. Berlin: Springer Verlag. pp. 35-46.
  10. Hopkins PN. Defining the challenges of familial hypercholesterolemia screening: introduction. J Clin Lipidol. 2010 Sep-Oct;4(5):342-5. Epub 2010 Aug 20. PubMed PMID: 21122675.
  11. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2000;4(29):1-123. Review. PubMed PMID: 11109029.
  12. Marks D, Wonderling D, Thorogood M, Lambert H, Humphries SE, Neil HA. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ. 2002 Jun 1;324(7349):1303. PubMed PMID: 12039822; PubMed Central PMCID: PMC113765.
  13. Datta BN, McDowell IF, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol. 2010 Aug;21(4):366-71. Review. PubMed PMID: 20613514.
  14. Defesche JC, Lansberg PJ, Umans-Eckenhausen MA, Kastelein JJ. Advanced method for the identification of patients with inherited hypercholesterolemia. Semin Vasc Med. 2004 Feb;4(1):59-65. Review. PubMed PMID: 15199434.
  15. Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001 Jan 20;357(9251):165-8. PubMed PMID: 11213091.
  16. Hamilton-Craig I. Case-finding for familial hypercholesterolemia in the Asia-Pacific region. Semin Vasc Med. 2004 Feb;4(1):87-92. PubMed PMID: 15199437.
  17. Leren TP, Manshaus T, Skovholt U, Skodje T, Nossen IE, Teie C, Sørensen S, Bakken KS. Application of molecular genetics for diagnosing familial hypercholesterolemia in Norway: results from a family-based screening program. Semin Vasc Med. 2004 Feb;4(1):75-85. Review. PubMed PMID: 15199436.
  18. Marais AD, Firth JC, Blom DJ. Familial hypercholesterolemia in South Africa. Semin Vasc Med. 2004 Feb;4(1):93-5. PubMed PMID: 15199438.
  19. Pocovi M, Civeira F, Alonso R, Mata P. Familial hypercholesterolemia in Spain: case-finding program, clinical and genetic aspects. Semin Vasc Med. 2004 Feb;4(1):67-74. Review. PubMed PMID: 15199435.
  20. Thorsson B, Sigurdsson G, Gudnason V. Systematic family screening for familial hypercholesterolemia in Iceland. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):335-8. PubMed PMID: 12588780.
  21. Watts GF, van Bockxmeer FM, Bates T, Burnett JR, Juniper A, O'Leary P. A new model of care for familial hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology. Heart Lung Circ. 2010 Jul;19(7):419-22. Epub 2010 Apr 3. PubMed PMID: 20363671.
  22. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. NICE clinical guideline CG71.
    http://www.nice.org.uk/guidance/CG71
  23. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, Daniels SR, Gidding SS, de Ferranti SD, Ito MK, McGowan MP, Moriarty PM, Cromwell WC, Ross JL, Ziajka PE. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S1-8. Epub 2011 Apr 12. PubMed PMID: 21600525.
  24. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9-17. Epub 2011 Apr 3. PubMed PMID: 21600530.
  25. Developed with the special contribution of: European Association for Cardiovascular Prevention & Rehabilitation; Authors/Task Force Members, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees, Bax J, Vahanian A, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Filippatos G, Funck-Brentano C, Hasdai D, Hobbs R, Hoes A, Kearney P, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vardas P, Widimsky P, Windecker S; Document Reviewers:, Funck-Brentano C, Poldermans D, Berkenboom G, De Graaf J, Descamps O, Gotcheva N, Griffith K, Guida GF, Gulec S, Henkin Y, Huber K, Kesaniemi YA, Lekakis J, Manolis AJ, Marques-Vidal P, Masana L, McMurray J, Mendes M, Pagava Z, Pedersen T, Prescott E, Rato Q, Rosano G, Sans S, Stalenhoef A, Tokgozoglu L, Viigimaa M, Wittekoek ME, Zamorano JL. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011 Jun 28. [Epub ahead of print] PubMed PMID: 21712404.
  26. Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol. 2008 Aug;19(4):362-8. Review. PubMed PMID: 18607183.
  27. Varret M, Abifadel M, Rabès JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet. 2008 Jan;73(1):1-13. Epub 2007 Nov 16. Review. PubMed PMID: 18028451.
  28. Huijgen R, Kindt I, Fouchier SW, Defesche JC, Hutten BA, Kastelein JJ, Vissers MN. Functionality of sequence variants in the genes coding for the low-density lipoprotein receptor and apolipoprotein B in individuals with inherited hypercholesterolemia. Hum Mutat. 2010 Jun;31(6):752-60. PubMed PMID: 20506408.
  29. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin Genet. 2004 Dec;66(6):483-7. Review. PubMed PMID: 15521974.
  30. Leren TP, Finborud TH, Manshaus TE, Ose L, Berge KE. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 2008;11(1):26-35. Epub 2008 Jan 15. PubMed PMID: 18196915.
  31. Damgaard D, Larsen ML, Nissen PH, Jensen JM, Jensen HK, Soerensen VR, Jensen LG, Faergeman O. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis. 2005 May;180(1):155-60. Epub 2005 Jan 12. PubMed PMID: 15823288.
  32. Humphries SE, Cranston T, Allen M, Middleton-Price H, Fernandez MC, Senior V, Hawe E, Iversen A, Wray R, Crook MA, Wierzbicki AS. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med. 2006 Mar;84(3):203-14. Epub 2005 Dec 31. PubMed PMID: 16389549.
  33. Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, Hutten BA. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010 Feb 15;5(2):e9220. PubMed PMID: 20169164; PubMed Central PMCID: PMC2821409.
  34. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008 Nov 11;337:a2423. doi: 10.1136/bmj.a2423. PubMed PMID: 19001495; PubMed Central PMCID: PMC2583391.
  35. Austin MA, Zimmern RL, Humphries SE. High "population attributable fraction" for coronary heart disease mortality among relatives in monogenic familial hypercholesterolemia. Genet Med. 2002 Jul-Aug;4(4):275-8. PubMed PMID: 12172393.
  36. Arambepola C, Farmer AJ, Perera R, Neil HA. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis. 2007 Dec;195(2):339-47. Epub 2006 Nov 13. Review. PubMed PMID: 17097660.
  37. Avis HJ, Vissers MN, Stein EA, Wijburg FA, Trip MD, Kastelein JJ, Hutten BA. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2007 Aug;27(8):1803-10. Epub 2007 Jun 14. Review. PubMed PMID: 17569881.
  38. Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics. 2007 Jul;120(1):e189-214. Review. PubMed PMID: 17606543.
  39. O'Gorman CS, Higgins MF, O'Neill MB. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. Pediatr Cardiol. 2009 May;30(4):482-9. Epub 2009 Feb 3. Review. PubMed PMID: 19189168.
  40. Shafiq N, Bhasin B, Pattanaik S, Pandhi P, Venkateshan SP, Singh M, Malhotra S. A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia. Int J Clin Pharmacol Ther. 2007 Oct;45(10):548-55. Erratum in: Int J Clin Pharmacol Ther. 2008 Jan;46(1):41. PubMed PMID: 17966840.
  41. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, Gylling H. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD006401. Review. PubMed PMID: 20614444.
  42. Calonge N, Guirguis-Blake J. Screening for familial hypercholesterolaemia. BMJ. 2007 Sep 22;335(7620):573-4. PubMed PMID: 17884865; PubMed Central PMCID: PMC1988985.
  43. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, Wijburg FA, Kastelein JJ, Hutten BA. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007 Aug 7;116(6):664-8. Epub 2007 Jul 30. PubMed PMID: 17664376.
  44. van der Graaf A, Kastelein JJ, Wiegman A. Heterozygous familial hypercholesterolaemia in childhood: cardiovascular risk prevention. J Inherit Metab Dis. 2009 Dec;32(6):699-705. Epub 2009 Oct 31. Review. PubMed PMID: 19898954.
  45. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJ, Kastelein JJ. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004 Jan 31;363(9406):369-70. PubMed PMID: 15070569.
  46. Guardamagna O, Restagno G, Rolfo E, Pederiva C, Martini S, Abello F, Baracco V, Pisciotta L, Pino E, Calandra S, Bertolini S. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr. 2009 Aug;155(2):199-204.e2. Epub 2009 May 15. PubMed PMID: 19446849.
  47. Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S46-51. Epub 2011 Apr 8. PubMed PMID: 21600529.
  48. US Preventive Services Task Force. Screening for lipid disorders in children: US Preventive Services Task Force recommendation statement. Pediatrics. 2007 Jul;120(1):e215-9. PubMed PMID: 17606545.
  49. Daniels SR. Screening for familial hypercholesterolemia: what is the most effective strategy? Nat Clin Pract Cardiovasc Med. 2008 Mar;5(3):130-1. Epub 2007 Dec 4. PubMed PMID: 18059381.
  50. Daniels SR, Greer FR; Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008 Jul;122(1):198-208. Review. PubMed PMID: 18596007.
  51. Jenssen BP, Jacobson MS. Screening adolescents for lipid disorders: what is the best approach? Adolesc Med State Art Rev. 2008 Dec;19(3):507-20, x. Review. PubMed PMID: 19227389.
  52. McCrindle BW, Urbina EM, Dennison BA, Jacobson MS, Steinberger J, Rocchini AP, Hayman LL, Daniels SR; American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee; American Heart Association Council of Cardiovascular Disease in the Young; American Heart Association Council on Cardiovascular Nursing. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation. 2007 Apr 10;115(14):1948-67. Epub 2007 Mar 21. PubMed PMID: 17377073.
  53. Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011 Jun;5(3 Suppl):S30-7. Epub 2011 Apr 5. PubMed PMID: 21600527.
  54. Koeijvoets KC, Wiegman A, Rodenburg J, Defesche JC, Kastelein JJ, Sijbrands EJ. Effect of low-density lipoprotein receptor mutation on lipoproteins and cardiovascular disease risk: a parent-offspring study. Atherosclerosis. 2005 May;180(1):93-9. Epub 2004 Dec 19. PubMed PMID: 15823280.
  55. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation. 2005 Nov 15;112(20):3168-73. PubMed PMID: 16286607.
  56. Souverein OW, Defesche JC, Zwinderman AH, Kastelein JJ, Tanck MW. Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia. Eur Heart J. 2007 Feb;28(3):299-304. Epub 2006 Nov 7. PubMed PMID: 17090611.
  57. Sijbrands EJ, Westendorp RG, Paola Lombardi M, Havekes LM, Frants RR, Kastelein JJ, Smelt AH. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis. 2000 Apr;149(2):421-5. PubMed PMID: 10729393.
  58. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC. Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation. 2002 Dec 10;106(24):3031-6. PubMed PMID: 12473547.
  59. Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J; American Heart Association Expert Panel on Population and Prevention Science; American Heart Association Council on Cardiovascular Disease in the Young; American Heart Association Council on Epidemiology and Prevention; American Heart Association Council on Nutrition, Physical Activity and Metabolism; American Heart Association Council on High Blood Pressure Research; American Heart Association Council on Cardiovascular Nursing; American Heart Association Council on the Kidney in Heart Disease; Interdisciplinary Working Group on Quality of Care and Outcomes Research. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation. 2006 Dec 12;114(24):2710-38. Epub 2006 Nov 27. Review. PubMed PMID: 17130340.
  60. Shafiq N, Singh M, Kaur S, Khosla P, Malhotra S. Dietary treatment for familial hypercholesterolaemia. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD001918. Review. PubMed PMID: 20091526.
  61. Hadfield SG, Horara S, Starr BJ, Yazdgerdi S, Marks D, Bhatnagar D, Cramb R, Egan S, Everdell R, Ferns G, Jones A, Marenah CB, Marples J, Prinsloo P, Sneyd A, Stewart MF, Sandle L, Wang T, Watson MS, Humphries SE; Steering Group for the Department of Health Familial Hypercholesterolaemia Cascade Testing Audit Project. Family tracing to identify patients with familial hypercholesterolaemia: the second audit of the Department of Health Familial Hypercholesterolaemia Cascade Testing Project. Ann Clin Biochem. 2009 Jan;46(Pt 1):24-32. Epub 2008 Nov 21. PubMed PMID: 19028807.
  62. Newson AJ, Humphries SE. Cascade testing in familial hypercholesterolaemia: how should family members be contacted? Eur J Hum Genet. 2005 Apr;13(4):401-8. Review. PubMed PMID: 15657617.
  63. Hopkins PN. Encouraging appropriate treatment for familial hypercholesterolemia. Clin Lipidol. 2010; 5:339-354.
This knol is part of the collection: PLoS Currents: Evidence on Genomic Tests
« Previous (Use of Epidermal Growth Factor Recep...
(Thiopurine methyltransferase (TPMT) ... Next »
Cascade Screening for Familial Hypercholesterolemia (FH) - a knol by Renée M. Ned
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)